From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

Contributed by: Business Wire

Logo

Images

PharmaEssentia founder and CEO, Dr. Ko-Chung Lin

Business Wire embedded0

Tags

Biotechnology

Health

Pharmaceutical

Clinical Trials

Oncology

ropeginterferon alfa-2b

More Like This

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

Portrait: Dr. Rudolf Widmann | Member of the Board of Directors & Founder | AOP Health | Photocredit: AOP Health | Ospelt Photography

ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b)

Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)

Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health

Dr. Rudolf Widmann, Founder of AOP Health, Photo credit: AOP Health/Studio Koekart

ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH

PR Newswire associated0

Norgine strengthens rare disease portfolio with acquisition of Theravia